Abstract. Scavenger receptor class B type I (SR-BI), a well-documented high-density lipoprotein receptor, has been implicated in the development and progression of human cancer. However, little is known regarding the expression profile and clinical value of SR-BI in gastric adenocarcinoma. In the present study immunohistochemistry analysis was performed on a well-annotated gastric adenocarcinoma tissue microarray to investigate the association between SR-BI expression and clinicopathological parameters or patient outcome. The results revealed that SR-BI expression was detected in 69% of the 84 gastric adenocarcinomas. Moreover, a significant association was observed between low SR-BI expression and poor histological grade, higher Tumor-Node-Metastasis T stage, higher N stage and diffuse type carcinoma. Low SR-BI expression was also significantly associated with a shorter overall survival time in patients with gastric adenocarcinoma, although it was not an independent prognostic factor. Overall, the results of the present study demonstrated that SR-BI was possibly involved in gastric carcinogenesis and could be used as a biomarker to predict malignancy of gastric adenocarcinoma.
Introduction
Gastric adenocarcinoma is a major contributor to the global health burden, ranking as the fifth most common type of malignancy worldwide (1) . Gastric adenocarcinoma is the second-leading cause of cancer death owing to its poor prognosis (2) . The identification of novel biomarkers with potential prognostic value would aid the assessment of patient prognosis and the selection of therapeutic treatments for individual patients with gastric adenocarcinoma.
Scavenger receptor class B type I (SR-BI) is a well-documented high-density lipoprotein (HDL) receptor, which is most abundantly expressed in liver and the steroidogenic tissues, including the ovaries, testes and adrenal glands (3) . SR-BI mediates the selective uptake of HDL cholesteryl esters and the bidirectional transfer of unesterified cholesterol between cells and HDL. In addition, SR-BI serves a role in sepsis, adaptive immune and hepatitis C virus entry (4) (5) (6) . It is becoming increasingly apparent that SR-BI serves a role in cancer development (7, 8) . Pronounced expression of SR-BI was observed in a variety of carcinomas, including hepatoma, prostate, breast, colorectal, pancreatic, ovarian, and nasopharyngeal cancer (9) (10) (11) (12) . Moreover, SR-BI has been demonstrated to exert a profound influence on the proliferation, migration and invasion of breast and prostate cancer cells (7, 8) . In human stomach, Lobo et al (13) reported that SR-BI was not detected in epithelial, parietal, mucous and endocrinal cells. However, to the best of our knowledge, the status of SR-BI expression in gastric adenocarcinoma and its clinical significance have not been reported to date.
The present study evaluated the expression of SR-BI using a high-throughput tissue microarray containing 90 cases of gastric carcinomas, with the aim of investigating its association with clinicopathological variables and patient outcome. (17) with the synthetic peptide used to produce the antibody as a control. The slides were then visualized using a bright field microscope (Olympus CX31; Olympus Corporation, Tokyo, Japan) under x40 or x200 magnification.
Materials and methods

Human
Immunohistochemical evaluation. Immunohistochemical staining for SR-BI expression was evaluated and scored independently by two pathologists blinded to the clinicopathological characteristics and outcomes of the patients. The immunostaining scores were based on the staining intensity and the proportion of stained cells. Staining intensity was scored as follows: 0, negative; 1, weak; 2, moderate; and 3 strong. The percentage of positive-stained cells was scored as follows: 0, 0%; 1, <10%; 2, 10-50%; 3, 51-80%; and 4, >80%.
For each case, a modified immunoreactive score was obtained by multiplying the intensity and the percentage scores (18), with scores ranging from 0 to 12. Tumor specimens with a final score of 0-4 were considered to exhibit low expression and those with a final score of 6-12 were regarded to exhibit high expression. Discrepancies between the pathologists were resolved by consensus following discussion.
Statistical analysis. All statistical analyses were performed using SPSS software (version 19; IBM Corp., Armonk, NY, USA). The χ 2 test or Fisher's exact test was used to analyze the associations between SR-BI expression and clinicopathological factors. Survival analysis was performed using the Kaplan-Meier method, with the log-rank test used to compare (Fig. 1C and D) than in the diffuse type of gastric carcinomas ( Fig. 1E and F ) according to the Lauren classification (P<0.001). In addition, SR-BI expression was significantly associated with T stage (P<0.001) and N stage (P=0.010). However, no significant association was observed between SR-BI expression and age, gender, tumor size, tumor location, lymphatic invasion, distant metastasis or pTNM stage.
SR-BI expression and patient outcome.
The association between SR-BI expression and overall survival was assessed in gastric adenocarcinoma patients using univariate analysis. As shown in Fig. 2 , Kaplan-Meier survival curves indicated that patients with low SR-BI expression had a significantly shorter OS time compared with patients with high SR-BI expression (P=0.037 by log-rank test). The 5-year survival rate for gastric adenocarcinoma patients with low SR-BI expression was 28%, compared with 54% for the group with SR-BI high expression. Additionally, tumor size, grade, Lauren type, pTNM stage, T stage, N stage, distant metastasis and lymphatic invasion were also associated with the risk of death (Table III) . No prognostic associations were observed with age, gender, or tumor location. Furthermore, multivariate analysis using the Cox regression model revealed that T stage, N stage and lymphatic invasion were independently and significantly associated with survival (P=0.035, P=0.002 and P=0.013, respectively; Table IV ). However, SR-BI expression was not an independent prognostic factor.
Discussion
Multiple studies have found that SR-BI is implicated in the regulation of diverse tumor cell biology, including tumor cell proliferation, apoptosis, migration and invasion (7, 8) . The present study analyzed the expression of SR-BI in multiple gastric adenocarcinoma specimens and found that SR-BI immunoreactivity was present in 69% of cases. Specifically, high SR-BI expression was detected in 28.6% of patients, all of whom had intestinal type disease. In addition, low SR-BI expression was significantly associated with clinicopathological parameters indicative of a more aggressive tumor type, including poor histological grade, higher T stage, higher N stage and diffuse type carcinoma. Patients with low SR-BI expression had poorer prognoses in the patient cohort of the present study. The data from the normal gastric tissue were in line with the previous paper by Lobo et al (13) , which demonstrated that Table II . Association of SR-BI protein expression with clinicopathological characteristics in patients with gastric cancer (n=84). SR-BI was predominantly detected in the majority of cells in the fundic gland, but not in the normal gastric mucosa. As SR-BI was not detected in epithelial, parietal, mucous or endocrinal cells (13), we hypothesized that SR-BI might be mainly located in chief cells. Further immunofluorescence staining in future studies is warranted to determine the exact cellular location of SR-BI.
SR-BI expression, % (n) -----------------------------------
Gastric adenocarcinoma is a heterogeneous disease that can be classified into two major histological subtypes based on Lauren's criteria: Intestinal type and diffuse type adenocarcinomas. The intestinal type gastric adenocarcinoma is possibly preceded by precancerous changes in the gastric mucosa, including chronic atrophic gastritis, intestinal metaplasia and dysplasia (14, 19) . The progression of gastric fundic gland polyps and the transdifferentiation of chief cells was reported to be involved in the initiation of intestinal metaplasia (19) ; however, diffuse-type gastric carcinoma seems to be less associated with environmental influences and precancerous changes (19) , and it is believed to originate from mucous neck cells or stem cells (20) . Evidence indicates that the molecular profiles of these subtypes are distinct (21) (22) (23) (24) . In the present study, marked differences in SR-BI expression between the intestinal type and diffuse type supported the notion that distinct precursors and pathways led to the oncogenesis of the two types of gastric adenocarcinoma.
Epidemiological studies have provided evidence indicating the presence of strong associations between serum lipid profiles and gastric adenocarcinoma (25, 26) . Considerable alterations have been documented regarding serum total cholesterol, triglyceride, HDL cholesterol and low-density lipoprotein cholesterol levels in patients with gastric adenocarcinoma compared with those in non-cancer subjects (25) . In particular, low serum HDL-cholesterol was reported to be a negative prognostic factor for gastric adenocarcinoma patients (26) . Low-density lipoprotein receptor (LDLR) levels in diffuse type gastric adenocarcinoma were significantly lower than those in normal mucosa, but there was no significant difference between intestinal-type gastric adenocarcinoma and normal mucosa (27) . Caveolin-1 is a scaffolding protein that binds to cholesterol and is involved in intracellular cholesterol trafficking. Barresi et al (28) reported that caveolin-1 expression was significantly higher in intestinal-type gastric adenocarcinoma than in the diffuse type. Similar to LDLR and caveolin-1, SR-BI expression in intestinal-type cancer was also higher than that in diffuse-type cancer in the present study. The differences in the aforementioned cholesterol-trafficking proteins between the two histological types indicated the presence of distinct cholesterol metabolism in these adenocarcinomas, which warrants further investigation.
Previous studies have shown that certain HDL-cholesterolelevating drugs may regulate SR-BI protein expression. Statins increase SR-BI expression in several cell types, including macrophages (29) , adipocytes (30), keratinocytes (31) , and endothelial cells (32) . Fibrates can affect HDL metabolism in Overall survival mice by downregulating hepatic SR-BI protein levels (33, 34) . The commercial tissue microarray did not provide detailed information regarding the plasma lipoprotein profiles or drug treatments (e.g. statins and fibrates) of patients, meaning that the possible influence of these factors on SR-BI expression in gastric tissues could not be evaluated. Further study is therefore required to answer these questions. Several studies have reported the role of SR-BI in diverse solid tumors (7, 35, 36) . For instance, SR-BI was shown to mediate the proliferative and anti-apoptotic features of HDL in MCF-7 breast cancer cells through modulation of cholesterol metabolism (7, 8) . Twiddy et al (36) found that SR-BI downregulation caused a significant reduction in prostate-specific antigen production and decreased the viability of prostate cancer cell lines in vitro. Previous studies revealed that SR-BI was associated with more aggressive cancer phenotypes and could serve a tumor-promoting function in breast and prostate cancer (35, 37) . However, in gastric adenocarcinoma, the role of SR-BI appeared to be different. In contrast to the findings of those prior studies, low SR-BI expression was associated with the more aggressive phenotype contrarily. Therefore, the role of SR-BI may be complex and tissue-dependent, and it may have versatile functions in different types of cancer. In gastric fundic gland cells, SR-BI may be involved in the active exocytosis of pepsinogen, as a high degree of membrane cholesterol metabolism is required in this process (38) , whereas in gastric adenocarcinoma, the pepsin-secreting function of cells was diminished (38) . We hypothesized that this may be the reason for the downregulation of SR-BI in gastric adenocarcinoma.
Despite the strong association between SR-BI expression and multiple types of cancer, reports linking SR-BI to the clinical outcome of cancer patients are limited. The results of a previous study revealed that high SR-BI expression was an independent factor predictive of poor prognosis for patients with breast cancer (35) . Schörghofer et al (37) reported that high SR-BI expression was associated with shorter disease-free survival times in prostate cancer. On the contrary, in gastric adenocarcinoma, patients with low SR-BI expression had significantly poorer prognosis than patients with high SR-BI expression, indicating that different mechanisms were involved.
In summary, the results of the present study demonstrated that low SR-BI expression was associated with malignancy and unfavorable prognosis in patients with gastric adenocarcinoma. Further research is therefore warranted to clarify the role of SR-BI in gastric adenocarcinoma.
